Many phase II and phase III clinical trials are now underway to develop antibodies against PD-L1/PD-1 nexus and to investigate new immune checkpoint inhibitors in an effort to therapeutically manage the devastating GBM (13). This evidence concerns the gene PDCD1 and glioblastoma.